Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.

Yazmin Odia; Ludimila Cavalcante; Howard Safran; Steven Francis Powell; Pamela N. Munster; Wen Wee; Benedito A. Carneiro; Bruno R. Bastos; Francis J. Giles; Solmaz Sahebjam

doi:10.1200/JCO.2021.39.15_SUPPL.2051

Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.

Yazmin Odia
, Ludimila Cavalcante
, Howard Safran
, Steven Francis Powell
, Pamela N. Munster
, Wen Wee
, Benedito A. Carneiro
, Bruno R. Bastos
, Francis J. Giles
, Solmaz Sahebjam

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	39
DOIs	https://doi.org/10.1200/JCO.2021.39.15_SUPPL.2051
State	Published - May 28 2021

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1200/JCO.2021.39.15_SUPPL.2051License: Unspecified

Cite this

Odia, Y., Cavalcante, L., Safran, H., Powell, S. F., Munster, P. N., Wee, W., Carneiro, B. A., Bastos, B. R., Giles, F. J., & Sahebjam, S. (2021). Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors. Journal of Clinical Oncology, 39. https://doi.org/10.1200/JCO.2021.39.15_SUPPL.2051

Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors. / Odia, Yazmin; Cavalcante, Ludimila; Safran, Howard et al.
In: Journal of Clinical Oncology, Vol. 39, 28.05.2021.

Research output: Contribution to journal › Article › peer-review

Odia, Y, Cavalcante, L, Safran, H, Powell, SF, Munster, PN, Wee, W, Carneiro, BA, Bastos, BR, Giles, FJ & Sahebjam, S 2021, 'Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.', Journal of Clinical Oncology, vol. 39. https://doi.org/10.1200/JCO.2021.39.15_SUPPL.2051

Odia Y, Cavalcante L, Safran H, Powell SF, Munster PN, Wee W et al. Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors. Journal of Clinical Oncology. 2021 May 28;39. doi: 10.1200/JCO.2021.39.15_SUPPL.2051

@article{c1c13b7aec334827b6d88e5cc967a73b,

title = "Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.",

author = "Yazmin Odia and Ludimila Cavalcante and Howard Safran and Powell, \{Steven Francis\} and Munster, \{Pamela N.\} and Wen Wee and Carneiro, \{Benedito A.\} and Bastos, \{Bruno R.\} and Giles, \{Francis J.\} and Solmaz Sahebjam",

note = "2051 Background: GSK-3β, a serine/threonine kinase, is a key regulator of metabolism and glycogen biosynthesis. GSK-3β aberrant overexpression promotes tumor progression and chemotherapy resistance through NF-κB and p53-mediated apoptotic pathways. GSK-3β inhibition impacts immunomodulation through downregulation of checkpoints, such as PD-L1 and LAG-3, and increasing NK and T-cell mediated killing of tumor cells.",

year = "2021",

month = may,

day = "28",

doi = "10.1200/JCO.2021.39.15\_SUPPL.2051",

language = "American English",

volume = "39",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.

AU - Odia, Yazmin

AU - Cavalcante, Ludimila

AU - Safran, Howard

AU - Powell, Steven Francis

AU - Munster, Pamela N.

AU - Wee, Wen

AU - Carneiro, Benedito A.

AU - Bastos, Bruno R.

AU - Giles, Francis J.

AU - Sahebjam, Solmaz

N1 - 2051 Background: GSK-3β, a serine/threonine kinase, is a key regulator of metabolism and glycogen biosynthesis. GSK-3β aberrant overexpression promotes tumor progression and chemotherapy resistance through NF-κB and p53-mediated apoptotic pathways. GSK-3β inhibition impacts immunomodulation through downregulation of checkpoints, such as PD-L1 and LAG-3, and increasing NK and T-cell mediated killing of tumor cells.

PY - 2021/5/28

Y1 - 2021/5/28

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.2051

U2 - 10.1200/JCO.2021.39.15_SUPPL.2051

DO - 10.1200/JCO.2021.39.15_SUPPL.2051

M3 - Article

VL - 39

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.

Disciplines

Access to Document

Other files and links

Cite this